Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement
Drug Resistance Updates · 2025-03 · 79 · 101199
DOI: 10.1016/j.drup.2024.101199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-03. Verfasst von Yi Xu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Loma Linda University Cancer Center, Loma Linda, CA 92354, United States; Division of Hematology and Oncology, Department of Medicine, Loma Linda Uni…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chromosomal rearrangements (CR) initiate leukemogenesis in approximately 50 % of acute myeloid leukemia (AML) patients; however, limited targeted therapies exist due to a lack of accurate molecular and genetic biomarkers of refractory mechanisms during treatment. Here, we investigated the pathological landscape of treatment resistance and relapse in 16 CR-AML patients by monitoring cytogenetic, RNAseq, and genome-wide changes among newly diagnosed, refractory, and relapsed AML. First, in FISH-diagnosed KMT2A (MLL gene, 11q23)/AFDN (AF6, 6q27)-rearrangement, RNA-sequencing identified an unknown CCDC32 (15q15.1)/CBX3 (7p15.2) gene fusion in both newly diagnosed and relapsed samples, which is previously unknown in KMT2A/AFDN-rearranged AML patients. Second, the unreported CCDC32/CBX3 gene fusion significantly affected the expression of wild-type genes of both CCDC32 (essential for embryonic development) and CBX3 (an oncogene for solid tumors) during the relapse, as demonstrated by Quantitative PCR analyses. Third, we further confirmed the existence of triple biomarkers - KMT2A/AFDN (AF6, 6q27) rearrangement, the unknown CCDC32 (15q15.1)/CBX3 (7p15.2) gene fusion and chimeric RNA variants (treatment-resistant leukemic blasts harboring distinct breakpoints) in a 21-year-old male patient of rapid relapsed/refractory AML. Most intriguingly, in this work regarding 16 patients, patients 7 and 20 initially showed the KMT2A/AFDN gene fusion; upon relapse, patient 20 did not show this fusion. On the other hand, patient 7 retained the KMT2A/AFDN fusion at diagnosis and during the relapse, only identified by PCR and Sanger's Sequencing, not by cytogenetics. Interestingly, the chimeric CCDC32/CBX3 gene fusion persisted in the 21-year-old male patient over the diagnostic and relapse phases. Most intriguingly, the overexpression of CCDC32/CBX3 fusion gene in AML patient-specific MV4-11 cells confirms the functional validation, providing experimental evidence of the biological impact of the CCDC32/CBX3 fusion on AML pathogenesis and treatment resistance by promoting cell cycle progression, a mechanism through which AML evolves to become treatment-resistant. All these might exhort differential resistance to treatment. Thus, we found that prognostic and predictive triple biomarkers - KRAS mutated, dual fusions (KMT2A/AFDN, CCDC32/CBX3), and chimeric variants - might evolve with a potential oncogenic role of subclonal evolution for poor clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Loma Linda University Cancer Center, Loma Linda, CA 92354, United States; Division of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, CA 92354, United States; Division of Regenerative…
- Department of Neurology, University of California-Irvine School of Medicine, 200 S. Manchester Ave. Ste. 206, Orange, CA 92868, United States; CHOC Children's Research Institute, Children's Hospital of Orange County (CH…
- Division of Hematology and Oncology, Department of Medicine, Loma Linda University, Loma Linda, CA 92354, United States.
- Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, 4505 S Maryland Pkwy, Las Vegas, NV 89154, United States; School of Life Sciences, College of Sciences, University of Nevada, 4505 S Maryland P…
- Department of Pathology & Laboratory Medicine, Loma Linda University, Loma Linda, CA, United States.
- Loma Linda University Cancer Center, Loma Linda, CA 92354, United States; Biospecimen Laboratory, Loma Linda University Cancer Center, Department of Medicine and Basic Sciences, Loma Linda University School of Medicine,…
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- National Natural Science Foundation of China
- Loma Linda University
- CHOC Children's Foundation
- NIH
Zitieren
APA
Xu, Y., Li, S. C., Xiao, J., Liu, Q., Cherukuri, D., Liu, Y., Mirshahidi, S., Xu, J., Chen, X., Homa, D., Olea, J., Wu, K., Kelly, K. R., Sun, F., Huang, R., Wang, X., Wen, Q., Zhang, X., Ghiuzeli, C. M., …, & Zhong, J. F. (2025). Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement. Drug Resistance Updates, 79, 101199. https://doi.org/10.1016/j.drup.2024.101199
Vancouver
Xu Y, Li SC, Xiao J, Liu Q, Cherukuri D, Liu Y, et al. Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement. Drug Resistance Updates. 2025;79:101199. doi:10.1016/j.drup.2024.101199
BibTeX
@article{Xu2025,
author = {Xu, Yi and Li, Shengwen Calvin and Xiao, Jeffrey and Liu, Qian and Cherukuri, Durga and Liu, Yan and Mirshahidi, Saied and Xu, Jane and Chen, Xuelian and Homa, Dadrastoussi and Olea, Julian and Wu, Kaijin and Kelly, Kevin R and Sun, Fengzhu and Huang, Ruihao and Wang, Xiaoqi and Wen, Qin and Zhang, Xi and Ghiuzeli, Cristina M and Chong, Esther and Abdel-Azim, Hisham and Reeves, Mark E and Baylink, David J and Cao, Huynh and Zhong, Jiang F},
title = {Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement},
journal = {Drug Resistance Updates},
year = {2025},
volume = {79},
pages = {101199},
doi = {10.1016/j.drup.2024.101199}
}
EUVIMED